Accèdez sans limite aux 15 000 actualités du site et recevez gratuitement chaque semaine, la Newsletter Santé log avec les ...

ART-501, formerly known as ARD-501 or TLX-032 for Tulex, is a proprietary oral liquid extended-release formulation of an existing, well-tolerated opioid receptor modulating drug developed through a ...

Invivyd intends to use the net proceeds that it will receive from the offering, together with its existing cash and cash equivalents, for commercial preparedness for the potential launch of VYD2311, ...

Portsmouth Square, Inc. owns the Hilton San Francisco Financial District (558 rooms) with extensive meeting space, restaurant and lounge, and a five-level parking garage. The hotel operates under a ...

Researchers from UBC and Vancouver Coastal Health are developing natural plant compounds into a healing gel that could speed up recovery and prevent wounds from returning. VANCOUV ...

The provisional patent application, titled, “Raphael Pharmaceutical, Inc. / Rambam MedTech Formula for Treating Neutrophil-Dominant Autoimmune Diseases (including RA)” (No. 63/911,729), was filed ...

Yomi® S and YomiPlan® AI Platform Now FDA-Cleared, Offering Unprecedented Precision, Efficiency, and Access for Dentists and Patients ...

Lucid Capital Markets is acting as the sole book-running manager for the offering. The offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-268532) filed with ...

The live webcast will also be accessible in the Investors section of the Company’s web site. For those who cannot listen to the live broadcast, an online replay will be available in the Investors ...

This NDA submission is an important milestone, and it brings gedatolisib one step closer to becoming available for patients with HR+/HER2- advanced breast cancer,” said Brian Sullivan, CEO and ...

OSE Immunotherapeutics annonce que le Comité indépendant d’experts scientifiques (IDMC) recommande la poursuite d’ARTEMIA, l’essai pivot de Phase 3 de Tedopi® dans le cancer du poumon non à petites ...

Candel’s R&D Day will include presentations and panel discussions from its executive leadership, clinical investigators, scientific advisors, and key collaborators. The event will provide an extensive ...